Of note, the significantly qualitative differences of aCL IgG and aß2GPI IgG testing by LIA in APS patients and aPL+ carriers were confirmed by quantitative analyses of the respective median OD levels. This evidence concerns the gene FASLG and autoimmune polyendocrinopathy.